Please login to the form below
Decibel Therapeutics
This page shows the latest Decibel Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Biotech leaders jump into US free speech debate
Alnylam chief executive John Maraganore, Decibel Therapeutics’ CEO Steve Holtzman, Acorda CEO Ron Cohen and Jeremy Levin of Ovid Therapeutics are the main signatories to the letter published In Nature, but
Latest news
More from news
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Decibel Therapeutics expands leadership team
Hearing disorders specialist Decibel Therapeutics has expanded its leadership team and board of directors with four new appointments. ... products. . Steve Holtzman, president and chief executive of Decibel Therapeutics, said: “We are thrilled to
-
Decibel Therapeutics appoints former Biogen exec as president and CEO
Steven Holtzman succeeds interim CEO Kevin Starr. Decibel Therapeutics has appointed Steven Holtzman as its new president and chief executive officer, succeeding interim chief executive Kevin Starr.
More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- New study identifies drugs that are safe to use in COVID-19 treatment
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- BMS eyes approval for second Opdivo combo in kidney cancer
- Moderna inks R&D agreements with Vertex and Chiesi
- FDA hands BMS and bluebird bio a priority review for ide-cel
- Using Artificial Intelligence to Transform Pharma
- Session 4: Systems Innovation Insight and Thinking
- Transforming Unstructured Healthcare Information into Real-World Evidence & Life Saving Insights
- UK COVID-19 vaccine ‘challenge trials’ could intentionally infect participants with virus
- Keytruda doubles five-year survival rate in NSCLC
- EMA fast-tracks review of bluebird bio’s LentiGlobin for sickle cell disease
PMHub
Frontera Group
Welcome to Frontera Group, where our agencies immerse you in the world of the patient...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
